文献速递消化、代谢与肾脏急症心脑血管急症

激素治疗贝尔面瘫对2型糖尿病患者血糖控制的影响

Impact of steroid treatment for Bell's palsy on Glycemic control in patients with type 2 diabetes mellitus.
PubMed 文献 · Am J Emerg Med · 2026-07-01
一句话结论2型糖尿病贝尔面瘫患者用激素后急性血糖轻度升高、HHS风险增加(NNH=80),但HbA1c和DKA无显著差异,支持及时激素治疗并出院时做好血糖监测。

该回顾性队列研究利用TriNetX数据库纳入2010—2024年贝尔面瘫合并2型糖尿病患者6268例,按是否在诊断后10天内接受全身激素分层并做倾向评分匹配。主要终点为诊断后1—30天最近一次血糖,激素组高于未用激素组(162.4 vs 152.4 mg/dL,P<0.001)。诊断后1—6个月HbA1c无显著差异(7.24% vs 7.20%,P=0.43),DKA率无显著差异(1.10% vs 0.84%,P=0.32),但HHS发生率激素组更高(1.82% vs 0.57%,P<0.001,NNH=80)。作者认为结果为假说生成性,需前瞻性数据,但可支持急诊医生及时启动激素并出院时监测血糖。

要点

  • 贝尔面瘫合并T2DM患者使用全身激素后1—30天血糖轻度升高(162.4 vs 152.4 mg/dL,P<0.001),绝对差值小。
  • 激素组HHS发生率更高(1.82% vs 0.57%,P<0.001),每80例治疗增加1例HHS(NNH=80)。
  • 激素组与未用激素组DKA率无显著差异(1.10% vs 0.84%,P=0.32),HbA1c无显著差异(7.24% vs 7.20%,P=0.43)。
  • 研究为回顾性、假说生成性,尚不能据此改变激素作为贝尔面瘫主要治疗的定位,但提示出院时应安排血糖监测。

适用人群与场景

  • 2010—2024年TriNetX Research Network中诊断为贝尔面瘫、合并2型糖尿病的患者,共6268例。
  • 按是否在诊断后10天内接受全身皮质激素治疗分层,并以年龄、性别、种族、民族、降糖药物及合并症进行倾向评分匹配。

诊断标准与关键阈值

  • 原文未提及

处置流程与药物剂量

  • 原文未提及具体激素药名、剂量、途径、频次或疗程。
  • 原文结果可支持急诊医生及时启动激素治疗,并在出院时进行适当血糖监测。

红旗征与不能漏的情况

  • 激素治疗的T2DM贝尔面瘫患者HHS发生率升高(1.82% vs 0.57%,P<0.001;NNH=80),需警惕高渗高血糖状态。
  • DKA率两组无显著差异(1.10% vs 0.84%,P=0.32),但原文未提及具体处理措施。

研究设计与关键结果

  • 研究类型:回顾性队列研究,使用TriNetX Research Network数据库,样本量6268例T2DM贝尔面瘫患者,多中心数据。
  • 主要终点:诊断后1—30天最近一次血糖,激素组162.4 mg/dL vs 未用激素组152.4 mg/dL,P<0.001。
  • 次要终点:诊断后1—6个月HbA1c 7.24% vs 7.20%,P=0.43;3个月内DKA率1.10% vs 0.84%,P=0.32;HHS率1.82% vs 0.57%,P<0.001,NNH=80。

证据类型、等级与局限

  • 证据类型:回顾性队列研究(原文称假说生成性研究),需前瞻性数据验证。
  • 局限:回顾性设计、依赖数据库编码、原文未提及激素具体方案,可能存在混杂。

对床旁实践的改变

  • 对合并T2DM的贝尔面瘫患者,急诊医生可及时启动激素治疗,不应因高血糖顾虑而延迟。
  • 出院时应安排血糖监测,尤其警惕HHS(NNH=80),但原文未提及具体监测频率或靶目标。
  • 原文结果为假说生成性,尚不能据此制定确定性推荐;是否调整降糖方案或激素剂量需个体化,原文未提及。

指南或共识出处

  • 原文未提及

以上提炼依据论文摘要(全文未开放获取,或许可不允许翻译转载);全文请点「阅读原文」。

英文原文(摘要)· 点击展开

INTRODUCTION: Corticosteroids are the primary treatment for Bell's palsy, but use in patients with type 2 diabetes mellitus (T2DM) is often limited by hyperglycemia concerns. This study assessed steroid-associated glycemic outcomes in diabetic Bell's palsy patients.

METHODS: This retrospective cohort study used the TriNetX Research Network to identify patients diagnosed with Bell's palsy from 2010 to 2024. Patients were stratified by T2DM status and receipt of systemic corticosteroids within 10 days of diagnosis. Propensity score matching was performed on age, sex, race, ethnicity, diabetes medications, and comorbidities. The primary outcome was the most recent glucose within 1-30 days post-diagnosis. Secondary outcomes were the most recent HbA1c within 1-6 months post-diagnosis and rates of diabetic ketoacidosis (DKA) or hyperosmolar hyperglycemic state (HHS) within 3 months.

RESULTS: Among 6268 patients with Bell's palsy and T2DM, steroid-treated patients had higher glucose within 1-30 days post-diagnosis (162.4 vs. 152.4 mg/dL; P < 0.001). HbA1c within 1-6 months did not differ significantly (7.24% vs. 7.20%; P = 0.43). DKA rates did not differ significantly (1.10% vs. 0.84%; P = 0.32), and HHS occurred at a higher rate in steroid-treated T2DM patients (1.82% vs. 0.57%; P < 0.001; number needed to harm = 80).

CONCLUSION: Corticosteroids for Bell's palsy in T2DM are associated with a small absolute increase in acute glucose and HHS risk, while HbA1c and DKA rates were not significantly different. As a hypothesis-generating study, prospective data are needed before definitive recommendations can be made; however, these results may support emergency clinicians in initiating timely steroid therapy with appropriate glucose monitoring at discharge.

来源:Am J Emerg Med,查看原文。版权归原作者所有。

参考来源

  1. Lorenz FJ, Ma C, Kang Y, et al. Impact of steroid treatment for Bell's palsy on Glycemic control in patients with type 2 diabetes mellitus. Am J Emerg Med. 2026. PMID: 42456542. doi:10.1016/j.ajem.2026.06.048

供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。